November 16, 2026

  UPFRONT BRIEFING

The FDA spent the weekend telling Summit that progression-free survival is not survival. Ivonescimab's CRL in EGFR-mutant lung cancer is the first U.S. verdict on the PD-1xVEGF class, and every rival bispecific now knows where the bar sits. Meanwhile J&J is reportedly lining up $2.2B in cash for Ollin, whose eye drug started life at Innovent.

Innovent also picked up a CHMP nod for sintilimab, the drug the FDA turned away in 2022, alongside AstraZeneca's baxdrostat. Jefferies London opens today (16–19 Nov), so expect guidance and deal chatter all week, and the HELP committee votes on FDA nominee Heidi Overton on Wednesday.

TAPE ACTION

  • Healthcare outperformed, with XLV +0.5% against the S&P 500's (0.4%), while biotech slipped: XBI (0.4%), NBI (0.5%), BBC (1.4%). In single names, Windward Bio closed its Nasdaq debut at $28.50, 68% above its $17 IPO price, and Rezolute reported Phase 3 upLIFT data pre-market alongside a $100M raise.

  • October PPI rose 0.3% m/m against 0.4% expected, but the 6.5% annual rate was the fastest since November 2022. Daly and Collins both signalled more tightening, a December hike stays fully priced (CME) and the 10Y rose 5bp to 5.15%. Chips gave back part of the post-Huang rally, with AMD (8.8%) and Nvidia (2.0%) after a Truist downgrade; NDX (1.2%), RUT (0.3%), Dow +0.1%.

THE BIG 3

1️⃣ — FDA rejects Summit's ivonescimab over missing survival benefit

  • Summit and Akeso's ivonescimab plus platinum chemo drew a CRL in EGFR-mutated non-squamous NSCLC after third-gen EGFR TKI therapy (disclosed Sun 15 Nov; PDUFA was 14 Nov). FDA said a PFS benefit without statistically significant OS "does not support" a positive benefit-risk profile.

  • Why it matters: The FDA has now put the bar in writing: in post-TKI EGFR-mutant NSCLC, a PFS win without a statistically significant OS gain does not establish effectiveness. HARMONi's primary OS analysis trended positive but missed, and the post-hoc HR of 0.76 on longer follow-up did not move reviewers. Summit named no resubmission path, so the U.S. case shifts to HARMONi-3 in first-line NSCLC, where squamous and non-squamous cohorts read out separately. SMMT closed Friday at $14.15 and fell about 20% in Sunday overnight trading. BioNTech and BMS's pumitamig and every other PD-1xVEGF bispecific now inherit the same OS test, and AstraZeneca, Pfizer and RevMed were reportedly circling Summit before the letter.

  • Source: Endpoints

2️⃣ — J&J in talks to buy Ollin for up to $3.4B, FT reports

  • J&J is in advanced talks to buy private Ollin Biosciences (ARCH, Mubadala) for up to $3.4B: $2.2B cash upfront plus up to $1.2B in milestones (FT, Sun 15 Nov). The lead asset, OLN324, is a VEGF/Ang2 bispecific heading into Phase 3 in DME and wet AMD.

  • Why it matters: If signed, this is $2.2B of cash for a VEGF/Ang2 bispecific aimed squarely at Roche's Vabysmo, which already owns that mechanism in wet AMD and DME. With only $1.2B in milestones, J&J would pay most of the value up front for an asset that has yet to start pivotal readouts. OLN324 originated at Innovent, so the deal would put China-sourced innovation inside a U.S. major while COINS Act rules are still being drafted. Ollin raised $330M in June, led by TCGX and ARCH, to run at least three Phase 3s; an early head-to-head favoured OLN324 over Vabysmo in DME and was closer in wet AMD. The FT says talks could still collapse, and neither side has confirmed.

3️⃣ — CHMP backs AstraZeneca's baxdrostat and Innovent's sintilimab

  • CHMP (9–12 Nov) recommended seven new medicines, including AstraZeneca's Baxfendy (baxdrostat) in hypertension, Innovent/Fortvita's Zybrivo (sintilimab) in 1L non-squamous NSCLC and Hansoh's Aumseqa (aumolertinib). Gazyvaro won a lupus extension, and Zevra's Meplyffa refusal was upheld on re-examination.

  • Why it matters: Baxdrostat is the commercial prize: AstraZeneca's aldosterone synthase inhibitor cut placebo-adjusted systolic pressure by 8.7 to 9.8 mmHg at week 12 in BaxHTN, and a European label opens uncontrolled and resistant hypertension ahead of Mineralys' lorundrostat. Sintilimab is the precedent. Lilly took it to the FDA in 2022 on China-only data, lost 14-1 at ODAC and drew a CRL; Europe now offers Innovent the Western label Washington withheld. Hansoh's aumolertinib also cleared. Two China-origin lung drugs in one CHMP cycle, in the same week the FDA rejected ivonescimab, sharpen the transatlantic gap for China-sourced assets. European Commission decisions usually follow within about two months.

EVERYTHING ELSE THAT BROKE

  • Cellectis may cut up to 70% of staff (about 160 of 229 roles), stopped enrollment in its lasme-cel and eti-cel CAR-T programs and is pivoting to in vivo editing (HEAL-101, HEAL-201); runway into 2H28. — Fierce Biotech

  • Novo's CagriSema posted about 21% weight loss at 68 weeks in REDEFINE 9 with lower doses. — PR

  • Rezolute's ersodetug met the primary endpoint of the Phase 3 upLIFT study in tumor hyperinsulinism: 13 of 16 patients cut IV glucose needs by at least 50%, with full topline due by mid-December. — Fierce Biotech

  • Novo submitted etavopivat in sickle cell disease, starting the regulatory clock on a billion-dollar deal asset. — BioPharma Dive

  • FDA approved AstraZeneca's Imfinzi plus Astellas/Pfizer's Padcev perioperatively in cisplatin-ineligible muscle-invasive bladder cancer; VOLGA (n=695) showed EFS HR 0.51 and OS HR 0.58 versus cystectomy alone. — Fierce Pharma

  • AstraZeneca is cutting about 600 U.S. sales jobs under a $1.5B savings plan. — Fierce Pharma

  • Milestone cut 20% of staff as Cardamyst generated $1M in Q3 sales. — Endpoints

  • CMS delayed enforcement of the stricter Medicaid work requirements by six months. — STAT

DEAL FLOW

Track the Deals Shaping Biotech

Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.

M&A / BD&L

  • J&J / Ollin Biosciences: advanced talks to acquire for up to $3.4B ($2.2B upfront cash plus up to $1.2B milestones), OLN324 VEGF/Ang2 bispecific; a deal could be announced as soon as Monday (FT, unconfirmed). — Reuters

VC / PRIVATE FINANCINGS

  • Sofinnova Partners closed Sofinnova Crossover II at €725M (~$815M), its largest fund, for about 15 late-stage, mostly European companies; first cheques went to CellCentric and Hemab (fund close). — Fierce Biotech

IPO / FOLLOW-ON

  • Windward Bio (WWB) closed its Nasdaq debut at $28.50, up 68% on the $17 IPO price (~$1.69B market cap); $225M raised including Sanofi's private placement, closing 16 Nov. — Windward release

  • Rezolute (RZLT) priced ~$100M: 22,040,976 shares at $3.87 plus pre-funded warrants for up to 3.8M shares, led by Frazier Life Sciences; Morgan Stanley, Guggenheim and Cantor; close ~16 Nov. — SEC (pricing FWP)

  • Surrozen (SRZN) priced $60M: 1,894,540 shares at $31.67; Morgan Stanley, Guggenheim and Cantor; close ~16 Nov. — BioSpace

ACADEMIC CORNER

  • Tirzepatide in adolescents with obesity showed an 18.5% mean BMI reduction versus a 0.5% increase with placebo at 72 weeks. — JAMA

  • SURMOUNT-ADOLESCENTS commentary sharpened the case for pediatric obesity pharmacotherapy as evidence continues to build. — JAMA

  • Ribupatide posted phase 3 weight-loss data in adults in China with overweight or obesity without diabetes. — JAMA

Know someone who'd like this?

Forward it along. It takes ten seconds and means a lot to us.

PFS gets you into the room. OS gets you the label.

— The BioBucks Team